{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ellipticines : Questions médicales les plus fréquentes",
"headline": "Ellipticines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ellipticines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ellipticines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carbazoles",
"url": "https://questionsmedicales.fr/mesh/D002227",
"about": {
"@type": "MedicalCondition",
"name": "Carbazoles",
"code": {
"@type": "MedicalCode",
"code": "D002227",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.300.148"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ellipticines",
"alternateName": "Ellipticines",
"code": {
"@type": "MedicalCode",
"code": "D004611",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elaine C O'Sullivan",
"url": "https://questionsmedicales.fr/author/Elaine%20C%20O%27Sullivan",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Florence O McCarthy",
"url": "https://questionsmedicales.fr/author/Florence%20O%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Hao Lu",
"url": "https://questionsmedicales.fr/author/Hao%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Manli Liu",
"url": "https://questionsmedicales.fr/author/Manli%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Hubei Biopesticide Engineering Research Centre, Hubei Academy of Agricultural Sciences, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Wenjia Lu",
"url": "https://questionsmedicales.fr/author/Wenjia%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Low-molecular weight inhibitors of the alternative complement pathway.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36217774",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imr.13143"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plasma factor D is cross-sectionally associated with low-grade inflammation, endothelial dysfunction and cardiovascular disease: The Maastricht study.",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37406499",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.atherosclerosis.2023.06.079"
}
},
{
"@type": "ScholarlyArticle",
"name": "Minimal role for the alternative pathway in complement activation by HIT immune complexes.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/35996342",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jth.15856"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.",
"datePublished": "2022-11-24",
"url": "https://questionsmedicales.fr/article/36423588",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000527167"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epstein-Barr Virus Viral Processivity Factor EA-D Facilitates Virus Lytic Replication by Inducing Poly(ADP-Ribose) Polymerase 1 Degradation.",
"datePublished": "2022-10-26",
"url": "https://questionsmedicales.fr/article/36286483",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/jvi.00371-22"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérocycliques 3 noyaux",
"item": "https://questionsmedicales.fr/mesh/D006575"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carbazoles",
"item": "https://questionsmedicales.fr/mesh/D002227"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ellipticines",
"item": "https://questionsmedicales.fr/mesh/D004611"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ellipticines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ellipticines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ellipticines",
"description": "Comment diagnostiquer une tumeur sensible aux ellipticines ?\nQuels tests sont utilisés pour évaluer l'efficacité des ellipticines ?\nLes ellipticines sont-elles utilisées pour tous les types de cancer ?\nQuels signes cliniques indiquent un traitement par ellipticines ?\nComment évaluer les effets secondaires des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ellipticines",
"description": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?\nLes ellipticines provoquent-elles des effets secondaires ?\nComment reconnaître une réaction allergique aux ellipticines ?\nLes ellipticines affectent-elles le système immunitaire ?\nQuels signes indiquent une toxicité des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ellipticines",
"description": "Peut-on prévenir les cancers traités par ellipticines ?\nQuels facteurs de risque sont associés aux cancers traités par ellipticines ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?\nComment un mode de vie sain influence-t-il le risque de cancer ?\nLes examens de santé réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ellipticines",
"description": "Comment les ellipticines sont-elles administrées ?\nLes ellipticines sont-elles utilisées en monothérapie ?\nQuel est le mécanisme d'action des ellipticines ?\nQuelles sont les alternatives aux ellipticines ?\nComment surveiller l'efficacité du traitement par ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ellipticines",
"description": "Quelles complications peuvent survenir avec les ellipticines ?\nLes ellipticines peuvent-elles causer des dommages aux organes ?\nComment gérer les effets secondaires graves des ellipticines ?\nLes ellipticines augmentent-elles le risque de récidive du cancer ?\nQuels sont les risques de surdosage d'ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ellipticines",
"description": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?\nL'hérédité joue-t-elle un rôle dans le risque de cancer ?\nL'alimentation influence-t-elle le risque de cancer ?\nLe stress est-il un facteur de risque pour le cancer ?\nLes infections virales augmentent-elles le risque de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+Factor+D&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur sensible aux ellipticines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par biopsie et analyses histopathologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des ellipticines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM et des marqueurs tumoraux sont utilisés."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont principalement efficaces contre certains cancers comme le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un traitement par ellipticines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de progression tumorale ou de résistance aux autres traitements peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des ellipticines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des examens cliniques et des questionnaires de qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, fatigue, perte de poids et changements d'appétit."
}
},
{
"@type": "Question",
"name": "Les ellipticines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent causer nausées, vomissements, et troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux ellipticines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Les ellipticines affectent-elles le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une toxicité des ellipticines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de toxicité incluent fatigue extrême, saignements inhabituels et jaunisse."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les cancers traités par ellipticines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives incluent un mode de vie sain et des dépistages réguliers."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux cancers traités par ellipticines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition à des agents carcinogènes et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il le risque de cancer ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant alimentation équilibrée et exercice, peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les examens de santé réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement des anomalies et d'initier un traitement rapide."
}
},
{
"@type": "Question",
"name": "Comment les ellipticines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse ou orale."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées en monothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées seules ou en association avec d'autres traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des ellipticines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles agissent en interférant avec l'ADN des cellules cancéreuses, inhibant leur prolifération."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives aux ellipticines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les alternatives incluent d'autres chimiothérapies, thérapies ciblées et immunothérapies."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement par ellipticines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par des examens d'imagerie et des bilans sanguins réguliers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les ellipticines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des saignements et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les ellipticines peuvent-elles causer des dommages aux organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des toxicités hépatiques et rénales, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires graves des ellipticines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'ajustement de la dose, l'utilisation de médicaments symptomatiques et le suivi."
}
},
{
"@type": "Question",
"name": "Les ellipticines augmentent-elles le risque de récidive du cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire le risque de récidive, mais un suivi régulier est essentiel."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de surdosage d'ellipticines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le surdosage peut entraîner des effets toxiques graves, nécessitant une intervention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent le tabagisme, l'exposition à des produits chimiques et l'âge."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le risque de cancer ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer certaines tumeurs."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de cancer ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en fruits et légumes peut réduire le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour le cancer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que le stress ne soit pas un facteur direct, il peut affecter le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections virales augmentent-elles le risque de cancer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales, comme le HPV, sont liées à un risque accru de cancer."
}
}
]
}
]
}
Dysregulation of the alternative complement pathway predisposes individuals to a number of diseases. It can either be evoked by genetic alterations in or by stabilizing antibodies to important pathway...
The complement system, particularly the alternative complement pathway, may contribute to vascular damage and development of cardiovascular disease (CVD). We investigated the association of factor D, ...
In 2947 participants (50.6% men, 59.9 ± 8.2 years, 26.5% type 2 diabetes [T2D], oversampled) we measured markers of low-grade inflammation (LGI, composite score, in SD) and, endothelial dysfunction (E...
Factor D (per SD) significantly associated with LGI (0.171 SD [0.137; 0.205]), ED (0.158 SD [0.123; 0.194]) and CVD (OR 1.15 [1.04; 1.27]) but not significantly with cIMT (-6.62 μm [-13.51; 0.27]) or ...
Plasma factor D is independently associated with LGI, ED, and prevalent CVD but not with ABI or cIMT. Hence, greater plasma factor D concentration in CVD may potentially induce complement activation w...
Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative ...
These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies....
Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or fa...
Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and ...
Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to exa...
C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options....
A double-blind, placebo-controlled study in patients with C3G and a single-arm, open-label study in patients with C3G or IC-MPGN treated with danicopan are reported. The studies evaluated pharmacokine...
Optimal systemic concentrations of danicopan were not achieved for complete and sustained inhibition of AP, although there was evidence that blockade of FD reduced AP activity shortly after drug admin...
While demonstrating a favorable safety profile, danicopan resulted in incomplete and inadequately sustained inhibition of AP, probably due to limitations in its PK/PD profile in C3G, leading to lack o...
Gammaherpesviruses, including Epstein-Barr virus (EBV), are important human pathogens because they are associated with various tumors. Poly(ADP-ribose) polymerase 1 (PARP1) is a multifunctional host n...
Fibromyalgia (FM) is a syndrome characterized by chronic musculoskeletal pain. Its clinical symptoms include both somatic and psychiatric symptoms, making the treatment of FM extremely challenging. Th...
In this study, we screened genes and secreted factors that play key roles in FM through bioinformatics and big data analysis. Furthermore, we performed CCK-8, qRT-PCR, glucose, ATP and lactate content...
In bioinformatics and big data analysis, we identified CFD was negatively correlated with the pro-inflammatory factor IL-6 and positively correlated with the anti-inflammatory factor IL-4, which sugge...
In summary, based on bioinformatic methods and big data mining we obtained a new target CFD for FM, and further experiments verified that CFD has significant inhibition of ATP-induced neuropathic pain...
The aim of the study is to evaluate the effect of vitamin D supplementation alone on the adipokine profile of postmenopausal women....
In this randomized clinical trial, 160 women were randomized to 2 groups: oral supplementation with 1,000 IU cholecalciferol/d (vitamin D, n = 80) or placebo (PL, n = 80). Women with amenorrhea 12 mon...
After 9 months, 25-hydroxyvitamin D concentrations increased from 15.0 ± 7.5 to 27.5 ± 10.4 ng/mL (+45.4%) in the vitamin D group and decreased from 16.9 ± 6. to 13.8 ± 6.0 ng/mL (-18.5%) in the PL gr...
Daily supplementation with 1,000 IU of vitamin D alone was associated with an increase in adiponectin and a decrease in resistin, suggesting a beneficial effect on the adipokine profile of postmenopau...
The complement system appears to be involved in the pathogenesis of venous thromboembolism (VTE). We investigated the association of complement factors (CF) B, D, and the alternative pathway convertas...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by episodic hemolysis, with additional clinical manifestations including thrombosis and bone marrow failure. Th...
We systematically searched for articles on PubMed, Web of Science, and three publishers Springer, Elsevier, Wiley up to May 6, 2024....
Danicopan acts on the alternative pathway of the complement cascade, preferentially controlling C3 fragment-mediated extravascular hemolysis. Recommended dosage is 150 mg orally three times a day, whi...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to a global health outbreak known as the COVID-19 pandemic which has been lasting since March 2020. Vaccine became accessible to people...